CardioMech Raises $13 Million for Transcatheter Mitral Chordal Repair Technology
CardioMech AS (“CardioMech”) announced that the company successfully raised $13 Million in capital in addition to the $18.5 Million Series A financing in 2020 bringing total funding to $42 Million. CardioMech...
NeoChord Announces Successful Completion of First-in-Human Procedure with its Mitral Chordal Repair Technology
NeoChord, Inc. (“NeoChord”) announced on October 4, 2021 that it successfully completed a first-in-human procedure with the NeXuS Transcatheter Mitral Chordal Repair (TMVr) device NeoChord is developing. NeoChord also reported...
